NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Artemis Medicare released its Q2 and H1 FY27 earnings conference call transcript, reporting consolidated Q2 FY27 revenue of ₹311 crore, up 13.2% YoY, and PAT of ₹31 crore, up 3.7% YoY. Consolidated EBITDA stood at ₹62.89 crore (20.2% margin), while the flagship Gurugram hospital delivered its highest-ever EBITDA margin of 23.8%. Management detailed expansion initiatives to reach ~2,000 operational beds over 3-5 years, including the ramp-up of the 300-bed Raipur facility launched in July 2026, adding 250 beds via Gurugram Tower 4, and a proposed 650+ bed facility in South Delhi expected by Q4 FY29-FY30.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the formal transcript for the Q2 & H1 FY27 earnings conference call held on November 2, 2026.
ஏன் இது முக்கியம்Provides granular operational insights into the Gurugram flagship margin profile, early performance of the Raipur hospital, and multi-year bed addition roadmap toward ~2,000 beds.
📅 குறுகிய காலம்Stable operational momentum supported by Gurugram's peak margin performance and early contributions from Raipur.
📈 நீண்ட காலம்Substantial structural expansion if management successfully scales bed capacity from ~700 to ~2,000 beds across NCR and Central India over 3-5 years.
⚠ அபாய எச்சரிக்கைகள்
High reliance on international patient flow (~30% of revenue)
Initial gestation EBITDA drag or slower ramp-up at the newly operational 300-bed Raipur facility
👀 கவனிக்க வேண்டியவை
Track the occupancy and ARPOB ramp-up at the newly opened 300-bed Artemis Shanti Hospital in Raipur, along with capex milestones for Tower 4 in Gurugram.
Artemis Medicare Q2 FY27 Net Profit Rises 3.7% YoY to ₹31.1 Cr; Targets ~2,000 Beds by 2030
Artemis Medicare reported a 13.2% YoY growth in consolidated operations revenue to ₹311.04 Cr for Q2 FY27, with PAT rising 3.7% YoY to ₹31.10 Cr. Gurugram flagship performance remained steady with bed occupancy improving to 68.1% (up 398 bps YoY) and ARPOB rising 6.6% YoY to ₹86,631. The newly operational Raipur unit exerted temporary operational drag, with consolidated operational EBITDA margin contracting 80 bps YoY to 17.6% (adjusted EBITDA margin was 20.7%). The company outlined a pipeline to double capacity to ~2,000 beds by 2030, anchored by an upcoming 650+ bed hospital in South Delhi and FAR expansion in Gurugram.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis Medicare released its Q2 & H1 FY27 earnings presentation, presenting operational data across Gurugram and Raipur along with its expansion roadmap through 2030.
ஏன் இது முக்கியம்While core Gurugram operations continue to post healthy ARPOB and margin expansion, initial gestation losses from the Raipur hospital temporarily compressed consolidated EBITDA margins to 17.6%.
📅 குறுகிய காலம்Stable operational execution at Gurugram offsets near-term margin dilution caused by the ramp-up of the Raipur facility.
📈 நீண்ட காலம்Doubling network capacity from ~1,000 to ~2,000 beds by 2030 through Delhi-NCR and Central India offers long-term revenue visibility, contingent on disciplined execution.
⚠ அபாய எச்சரிக்கைகள்
Gestation losses from new facilities (Raipur unit) diluting consolidated operating margins.
Execution and capex funding risks regarding the upcoming 650+ bed greenfield South Delhi facility.
👀 கவனிக்க வேண்டியவை
Track the breakeven trajectory of the newly launched Raipur hospital and monitor construction milestones for the 650+ bed South Delhi facility.
Q2 FY27 Consolidated Revenue Up 13.2% to Rs 311.04 Cr; Raipur Hospital Drags Consolidated PAT to +3.7%
Artemis Medicare reported a 13.2% YoY increase in consolidated revenue from operations to Rs 31,104 Lacs (Rs 311.04 Cr) for Q2 FY27. Core Gurugram hospital operations performed strongly, with revenue growing 14.5% to Rs 29,844 Lacs and PAT jumping 25.9% to Rs 4,043 Lacs, supported by ARPOB reaching Rs 86,631 and occupancy at 68.1%. However, consolidated PAT growth was subdued at 3.7% YoY to Rs 3,110 Lacs (Rs 31.10 Cr) due to initial operational drag from the newly launched Raipur unit (operational July 2026). Excluding Raipur, Adjusted Consolidated EBITDA grew 22.7% YoY to Rs 7,150 Lacs.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis reported Q2 FY27 earnings reflecting steady core hospital growth alongside initial gestation losses from the newly launched Raipur hospital.
ஏன் இது முக்கியம்While core hospital operational metrics (ARPOB and occupancy) continue to improve, overall reported margins and PAT growth are temporarily constrained by new hospital launch costs.
📅 குறுகிய காலம்The market is likely to weigh strong operational execution at Gurugram against the margin drag from the Raipur unit rollout.
📈 நீண்ட காலம்Successful scale-up in Raipur and the expansion beyond Gurugram are crucial to diversifying geographic risk and unlocking multi-year revenue growth.
⚠ அபாய எச்சரிக்கைகள்
Margin dilution from initial ramp-up and gestation of the new Raipur unit
Significant concentration risk with international patients contributing 29.7% of core revenue
👀 கவனிக்க வேண்டியவை
Track the ramp-up and breakeven timeline of the newly launched Raipur hospital, as well as the stability of international patient flows which make up ~30% of hospital revenue.
Q2 Standalone Revenue Up 13.3% YoY to ₹305.7 Cr; PAT Rises 3.3% to ₹30.95 Cr
Artemis Medicare Services reported standalone revenue from operations of ₹305.71 Cr for Q2 FY27 (quarter ended Sep 30, 2026), representing a 13.3% YoY growth compared to ₹269.78 Cr in Q2 FY26. Standalone net profit for the quarter rose 3.3% YoY to ₹30.95 Cr compared to ₹29.96 Cr in the year-ago period, though it remained largely flat QoQ against ₹31.05 Cr. For H1 FY27, standalone net profit expanded 20.7% YoY to ₹62.00 Cr on revenue of ₹587.72 Cr. Operating cash flow for H1 FY27 stood strong at ₹112.31 Cr, while capex deployment in property, plant, and equipment reached ₹112.36 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis approved and declared its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates sustained double-digit top-line growth (13.3% YoY) in line with expected growth rates (~13.8%), although bottom-line margin expansion was tempered in Q2 by higher operating and depreciation expenses.
📅 குறுகிய காலம்The results reflect steady operations without major negative surprises; stock reaction is likely to remain muted given flat QoQ net profit.
📈 நீண்ட காலம்Sustained capex investment (₹112.36 Cr in H1) will support capacity ramp-up and multi-specialty bed additions, sustaining medium-term revenue expansion.
⚠ அபாய எச்சரிக்கைகள்
High working capital drag visible in receivables expansion during H1 (₹40.47 Cr increase)
👀 கவனிக்க வேண்டியவை
Track the full consolidated performance release and management commentary regarding ARPOB trends and occupancy rates across newly expanded wings like Tower 3.
Artemis Medicare Receives ₹11.11 Cr CGST Show Cause Notice for FY23
Artemis Medicare Services has received a Show Cause Notice dated September 28, 2026, from the CGST department, Gurugram, alleging non-remittance of GST included in MRP charged on medicines and implants supplied to in-patients during FY22-23. The total tax demand is ₹11.11 Crore plus applicable interest and penalties, representing ~1.0% of TTM revenue (₹1,076 Cr) and ~10.7% of TTM net profit (₹103.4 Cr). The company noted that an earlier similar matter was stayed by the Punjab & Haryana High Court along with other hospital petitions, and it plans to file a writ petition to tag this notice with the existing stay.
உச்சம் நம்பிக்கை
என்ன மாறியதுCGST Department issued an ₹11.11 Cr Show Cause Notice for FY23 regarding taxability of medicines and consumables charged at MRP to in-patients.
ஏன் இது முக்கியம்The ₹11.11 Cr exposure accounts for ~10.7% of TTM net profit, representing an industry-wide dispute over GST treatment on composite healthcare services.
Quantum of claim: Rs. 11.11 Crore and interest & penalty thereonClaim vs TTM Revenue: ~1.03%Claim vs TTM PAT: ~10.74%Applicable Period: From April 1, 2022 to March 31, 2023
📅 குறுகிய காலம்Limited direct disruption expected as the company pursues an interim stay in line with earlier industry-wide court orders.
📈 நீண்ட காலம்An adverse judicial ruling across the healthcare sector regarding GST on in-patient supplies could impact hospital billing practices and margins.
⚠ அபாய எச்சரிக்கைகள்
Uncertain legal outcome pending court ruling
Potential liability for interest and penalties in addition to the principal ₹11.11 Cr
👀 கவனிக்க வேண்டியவை
Track the upcoming writ petition filing and interim relief or stay order from the Punjab & Haryana High Court regarding this ₹11.11 Cr notice.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Artemis Medicare Q1 PAT Surges 48.3% to ₹31.4 Cr; ₹800 Cr Capex Roadmap Outlined
Artemis Medicare reported a strong Q1 FY27 with consolidated revenue growing 12.7% YoY to ₹287.32 Cr and PAT increasing 48.3% to ₹31.44 Cr. The company has operationalized its 300-bed Raipur facility and is advancing Tower IV in Gurugram (200+ beds) to reach a 2,000-bed target by 2030. Management outlined a ₹800 Cr capex plan over the next three years, funded partly by a proposed QIP. Operational metrics improved with ARPOB reaching ₹85,690, while international patient revenue remained resilient at 27% despite geopolitical headwinds.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from planning to execution on its Raipur facility and has provided a granular breakdown of its ₹800 Cr capex strategy.
ஏன் இது முக்கியம்The expansion plan is highly material, with the ₹800 Cr capex representing approximately 74% of TTM revenue, aiming to double bed capacity and potentially expand margins to 23%+ through brownfield efficiencies.
Q1 FY27 PAT Growth (YoY): 48.3%Total Capex Plan (3 Years): ₹800 கோடிCapex vs TTM Revenue: ~74.3%Q1 EBITDA Margin: 21.5%Target Bed Capacity (2030): 2,000ARPOB: ₹85,690
📅 குறுகிய காலம்The stock may react positively to the strong bottom-line growth and margin expansion, alongside clarity on the expansion roadmap.
📈 நீண்ட காலம்Structural growth is expected as the company diversifies beyond Gurugram into Raipur and South Delhi, aiming for a ₹2,000 Cr top line from the flagship facility alone.
⚠ அபாய எச்சரிக்கைகள்
Execution risk of ₹800 Cr capex
Potential equity dilution from QIP
Geopolitical risks impacting the 27% international patient revenue stream
👀 கவனிக்க வேண்டியவை
Monitor the occupancy ramp-up at the newly operational Raipur facility and the timeline for regulatory clearances for Tower IV in Gurugram. Watch for the pricing and dilution impact of the upcoming QIP intended to fund the ₹800 Cr expansion.
48.3% PAT Growth in Q1 FY27; Artemis Reports Consolidated Revenue of ₹287 Cr
Artemis Medicare reported a strong start to FY27 with consolidated revenue growing 12.7% YoY to ₹287.32 Cr. Profitability outperformed revenue growth significantly, with EBITDA rising 27.9% to ₹61.82 Cr and PAT jumping 48.3% to ₹31.44 Cr. The flagship Gurgaon hospital remains the primary driver, showing improved bed utilization of 65.7% and a higher ARPOB of ₹85,690. A key strategic milestone was reached with the commencement of operations at the Raipur hospital in July 2026, marking the company's expansion beyond its core Delhi-NCR hub.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis delivered a high-growth quarter with significant margin expansion and successfully operationalized its first major expansion outside the Gurgaon hub in Raipur.
ஏன் இது முக்கியம்The sharp rise in PAT and EBITDA margins (reaching ~21.5% this quarter vs 17.5% TTM) demonstrates strong pricing power and efficiency. The Raipur expansion is a critical test of the company's ability to scale its brand geographically.
Consolidated Revenue (Q1 FY27): ₹287.32 கோடிConsolidated PAT (Q1 FY27): ₹31.44 கோடிARPOB (Gurgaon): ₹85,690EBITDA Growth (YoY): 27.9%Q1 வருவாய் vs TTM வருவாய்: 26.7%Overseas Revenue Contribution: 27.5%
📅 குறுகிய காலம்The stock is likely to react positively to the substantial earnings beat and margin expansion, alongside the positive news of the Raipur hospital commencement.
📈 நீண்ட காலம்The company is transitioning from a single-asset flagship model to a multi-city healthcare platform; success in Raipur and upcoming Delhi projects will be structural re-rating catalysts.
⚠ அபாய எச்சரிக்கைகள்
High geographical concentration in Gurgaon (~97% of Q1 revenue)
Potential short-term margin pressure from Raipur hospital ramp-up
Significant reliance on international medical travel (27.5% of revenue)
👀 கவனிக்க வேண்டியவை
Monitor the occupancy ramp-up and break-even timeline for the new Raipur facility, as initial costs may impact consolidated margins. Watch for the execution of planned greenfield/brownfield projects in Delhi to further diversify the revenue base.
200+ Bed Expansion: Artemis to Invest Rs 160-180 Cr in Gurugram Flagship Hospital
Artemis Medicare has approved a significant expansion of its flagship Gurugram hospital by adding 200+ beds through Tower IV. The project involves an investment of Rs 160-180 crore, representing approximately 15-17% of its TTM revenue, to be funded via internal accruals and debt. The expansion focuses on high-margin quaternary pediatric and advanced gynecology services with a 2-year execution timeline. Simultaneously, the company reported Q1 FY27 consolidated revenue of Rs 287.32 crore, a 12.7% increase over the same quarter last year.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board has formally approved a brownfield expansion (Tower IV) at its primary Gurugram site and released Q1 FY27 financial results showing steady growth.
ஏன் இது முக்கியம்The expansion targets high-value specialties in the premium Delhi-NCR market, which could further enhance the company's already strong ARPOB of Rs 81,248 and provide long-term revenue visibility.
Proposed Bed Addition: 200+ bedsInvestment Value: Rs 160 - 180 CrInvestment vs TTM Revenue: ~16.7%Q1 FY27 Revenue (Consolidated): Rs 287.32 கோடிCurrent Capacity Utilization: 65.7%Execution Timeline: ~2 years
📅 குறுகிய காலம்The announcement of growth-oriented capex alongside steady quarterly results is likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்This expansion structurally strengthens Artemis's position in the NCR healthcare market and supports its strategy of focusing on complex, high-margin clinical procedures.
⚠ அபாய எச்சரிக்கைகள்
Execution risk over the 2-year construction period
Potential margin pressure from increased depreciation and interest costs
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of Tower IV and the ramp-up of Tower 3 which was recently operationalized. Investors should also track the impact of new debt on the company's currently low D/E ratio of 0.28.
Artemis Medicare Q1 PAT up 45% YoY; Announces ₹180 Cr Expansion for 200+ Beds
Artemis Medicare reported a strong Q1 FY27 with consolidated revenue reaching ₹287.32 Cr, a 12.7% increase from ₹254.96 Cr in Q1 FY26. Standalone net profit grew 45% YoY to ₹31.05 Cr, driven by improved operational efficiencies and a capacity utilization of 65.7%. The Board approved a significant expansion of its flagship Gurugram hospital (Tower IV), adding 200+ beds with an investment of ₹160-180 Cr. This expansion, funded via internal accruals and debt, represents approximately 19% of the company's current net worth.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis has transitioned from planning to formalizing a major capacity expansion in Gurugram while delivering double-digit earnings growth.
ஏன் இது முக்கியம்The expansion targets high-demand quaternary pediatric and women's health services, allowing the company to scale its flagship hub where utilization is already healthy at 65.7%.
Q1 Consolidated Revenue: ₹287.32 கோடிQ1 Standalone PAT: ₹31.05 கோடிProposed Expansion Capex: ₹180 கோடிCapex vs Net Worth: 19.16%Proposed Bed Addition: 200+ unitsCapacity Utilization: 65.7%
📅 குறுகிய காலம்The stock is likely to react positively to the 45% YoY profit growth and the clear roadmap for capacity addition which addresses future growth constraints.
📈 நீண்ட காலம்The addition of 200+ beds in Gurugram and the phased 650+ bed expansion in Delhi (Vimhans) by FY29 suggests a structural shift toward becoming a much larger multi-hub healthcare provider.
⚠ அபாய எச்சரிக்கைகள்
Execution risk over the 2-year construction period
Potential margin sensitivity to international medical travel volumes
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the 24-month Tower IV expansion and the progress of the 650+ bed Vimhans project slated for FY29. Investors should also track the stability of international patient contributions, which remain a high-margin segment.
Artemis Medicare Shareholders Approve Fundraise; 98.68% Votes in Favor
Shareholders of Artemis Medicare Services Limited have passed a special resolution to raise funds through the issuance of equity shares or other eligible securities. The resolution received overwhelming support with 98.68% of the total 11.94 crore votes cast in favor. This approval provides the board with the mandate to secure capital for the company's stated growth objectives, including the acquisition of the remaining 35% stake in its cardiac centers and expansion into new geographies like Raipur and Delhi. The promoter group showed unanimous support, voting 100% in favor of the proposal.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have officially granted the company the authority to raise capital, moving the proposed fundraise from a board proposal to an actionable corporate event.
ஏன் இது முக்கியம்This capital is critical for Artemis to execute its growth strategy, specifically the 100% acquisition of its cardiac centers to improve operational efficiency and its expansion beyond the Gurugram hub into Raipur and Delhi.
Votes in Favor: 98.68%Total Votes Polled: 11,93,90,718Promoter Votes in Favor: 100.00%Institutional Votes in Favor: 92.79%Fundraise Amount: வெளியிடப்படவில்லை
📅 குறுகிய காலம்The successful passing of the resolution is a positive signal of shareholder confidence, though the immediate stock impact will depend on the eventual pricing and size of the fundraise.
📈 நீண்ட காலம்If the funds are deployed effectively into the planned cardiac center consolidation and geographic expansion, it could support the company's 13.8% expected growth rate and improve margins.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
Execution risk in new geographies (Raipur/Delhi)
Pricing of the new securities
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming board meetings for announcements regarding the specific quantum of funds to be raised, the instrument type (e.g., QIP, Rights Issue), and the issue price, as these will determine the extent of equity dilution.
300+ Bed Hospital Operations Commence in Raipur; Bed Capacity Increases by ~43%
Artemis Medicare has operationalized its 300+ bed multi-specialty hospital in Raipur, Chhattisgarh, as of July 9, 2026. This facility operates under a long-term Operations & Management (O&M) agreement, representing a significant asset-light expansion beyond its 700-bed Gurugram hub. The addition increases the company's total bed capacity by approximately 43%, aligning with its strategy to diversify geographically into Central India. Investors should note this move aims to reduce geographic concentration and leverage the company's clinical protocols in a new high-growth market.
உச்சம் நம்பிக்கை
என்ன மாறியதுArtemis has officially transitioned from a Delhi-NCR centric operator to a multi-regional player by starting its first major facility in Central India.
ஏன் இது முக்கியம்This expansion reduces dependence on the Gurugram hub and utilizes an asset-light O&M model, which can potentially improve Return on Capital Employed (ROCE) if the unit reaches profitability quickly.
New Bed Capacity: 300+ bedsExisting Bed Capacity: 700+ bedsCapacity Increase vs Existing: ~43%TTM வருவாய்: Rs 1076 கோடிCommencement Date: ஜூலை 9, 2026
📅 குறுகிய காலம்Positive sentiment is expected as the company meets its expansion timeline; however, initial quarters may see minor margin drag due to start-up costs and marketing.
📈 நீண்ட காலம்Structurally significant as it validates the company's ability to scale outside its home market; successful execution could lead to further O&M-based expansions.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in a new geography
Potential for lower ARPOB in Raipur compared to the Gurugram average of Rs 81,248
Competition from established local healthcare providers
👀 கவனிக்க வேண்டியவை
Monitor the occupancy ramp-up and Average Revenue Per Occupied Bed (ARPOB) at the Raipur facility over the next 2-4 quarters to assess its contribution to the TTM revenue of Rs 1076 Cr.
Artemis Medicare Announces Final Dividend of ₹0.45 per Share for FY 2025-26
Artemis Medicare Services Limited has recommended a final dividend of ₹0.45 per equity share (face value ₹1) for the financial year 2025-26. The company has fixed July 10, 2026, as the record date to determine eligible shareholders. This communication specifically outlines the Tax Deduction at Source (TDS) requirements, noting a 10% rate for resident shareholders with valid PAN and 20% for those without. Non-resident shareholders may opt for Double Taxation Avoidance Agreement (DTAA) benefits by submitting required documentation by July 15, 2026.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹0.45 per equity share for FY 2025-26.Record date for dividend entitlement is set for Friday, July 10, 2026.TDS of 10% applicable for resident individuals if total dividend exceeds ₹10,000 in the tax year.Non-resident withholding tax is set at 20% plus applicable surcharge and cess, subject to DTAA claims.Deadline for submission of tax-related documents to the RTA is Wednesday, July 15, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant or RTA and submit tax exemption forms like Form 121 by July 15, 2026, to avoid higher tax withholding.
Artemis Medicare Sets July 10 as Record Date for Re 0.45 Final Dividend
Artemis Medicare Services Limited has declared a final dividend of Re. 0.45 per equity share for the financial year 2025-26, which is 45% of the face value of Re. 1. The company has fixed July 10, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to approval at the upcoming 22nd Annual General Meeting (AGM) scheduled for July 31, 2026. Once approved, the payment will be processed within 30 days of the AGM date.
முக்கிய அம்சங்கள்
Final dividend of Re. 0.45 per equity share (45% payout) for FY 2025-26Record date for dividend eligibility fixed as Friday, July 10, 202622nd Annual General Meeting (AGM) to be held on July 31, 2026Remote e-voting period scheduled from July 28 to July 30, 2026Dividend payment to be completed within 30 days of shareholder approval
👀 கவனிக்க வேண்டியவை
Investors looking to qualify for the dividend should ensure they hold the shares in their demat account before the ex-dividend date, which typically precedes the July 10 record date. Long-term investors should note the steady payout as a sign of consistent shareholder returns.
Artemis Medicare Services Seeks Shareholder Approval to Raise up to ₹700 Crore
Artemis Medicare Services Limited has issued a postal ballot notice to seek shareholder approval for raising funds up to ₹700 crore. The capital is intended to be raised through the issuance of equity shares, convertible debentures, or other eligible securities via QIP, preferential issue, or private placement. The e-voting period for this special resolution is set from June 19, 2026, to July 18, 2026. This significant fundraise points toward potential expansion plans or strengthening of the company's balance sheet.
முக்கிய அம்சங்கள்
Proposed fundraise of an aggregate amount not exceeding ₹700 crore.Issuance methods include Qualified Institutions Placement (QIP), preferential issue, and private placement.The company may offer a discount of up to 5% on the floor price calculated as per SEBI ICDR Regulations.Remote e-voting period starts on June 19, 2026, and concludes on July 18, 2026.The resolution is proposed as a Special Resolution, requiring a 75% majority for approval.
👀 கவனிக்க வேண்டியவை
Investors should watch for the voting results and subsequent management commentary on the specific utilization of these funds. While equity issuance may lead to dilution, the scale of the fundraise suggests aggressive growth or acquisition plans in the healthcare sector.
Artemis Medicare Board Approves Fundraise Up To Rs. 700 Crores Via Equity Issuance
The Board of Artemis Medicare Services has approved a proposal to raise funds up to Rs. 700 crores through the issuance of equity shares or other eligible securities. This decision follows a prior intimation from February 2026 and will require shareholder approval via a postal ballot. The capital infusion is likely intended for expansion or debt restructuring, though specific utilization details are pending. The board has approved the draft Postal Ballot Notice to be circulated to members in due course.
முக்கிய அம்சங்கள்
Fundraising limit set at an aggregate amount not exceeding Rs. 700 crores.Issuance may include Equity Shares and/or other eligible securities under SEBI regulations.Shareholder approval to be sought via Postal Ballot as per the Board's decision on June 4, 2026.The board meeting commenced at 4:30 PM and concluded at 6:00 PM.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming Postal Ballot notice for specific details on fund utilization and potential equity dilution. While the fundraise signals growth intent, the pricing of the issuance will be a key factor for short-term stock movement.
Artemis Medicare FY26 PAT Jumps 26% to ₹104 Cr; Plans Expansion to 2,000 Beds by 2029
Artemis Medicare reported a strong FY26 with consolidated revenue growing 15.4% to INR 1,081 crores and PAT increasing 26.2% to INR 104 crores. The company maintained robust EBITDA margins of 20.2% for the full year, driven by high-complexity procedures and a strong international patient mix contributing 31% of revenue. Management outlined a clear growth path to increase bed capacity from 800 to 2,000 by 2029, supported by a board-approved INR 700 crore fundraise. Key upcoming milestones include the commissioning of the 300-bed Raipur facility in Q1 FY27.
முக்கிய அம்சங்கள்
FY26 consolidated revenue reached INR 1,081 crores with a 20.2% EBITDA margin and PAT of INR 104 crores.Q4 FY26 PAT grew 32.1% YoY to INR 30 crores, with ARPOB rising 7.3% to INR 84,571.International patient revenue grew 26.9% YoY, maintaining a high contribution of 31% to total revenue.Aggressive expansion plan to reach 2,000 beds by 2029, including new facilities in Raipur (300 beds) and South Delhi (650 beds).Board approved fundraising of up to INR 700 crores to support upcoming capital expenditure and growth initiatives.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the Raipur facility in Q1 FY27 and the execution of the INR 700 crore fundraise. The company's ability to maintain high ARPOB and a strong international patient mix makes it a robust play in the premium healthcare segment.
Artemis Medicare FY26 Results: Recommends 45% Dividend and Appoints New Independent Directors
Artemis Medicare Services Limited has recommended a final dividend of ₹0.45 per equity share (45% of face value) for the financial year ended March 31, 2026. The board has strengthened its leadership by appointing Mr. Tapan Mitra and proposing Dr. Girdhar J. Gyani as Independent Directors for three-year terms. Additionally, the company has extended the utilization period for unspent funds from its preferential issue by 18 months to ensure strategic capital deployment. The statutory auditors, M/s. T R Chadha & Co LLP, have also been re-appointed for a second five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.45 per equity share of face value ₹1 (45% payout)Appointed Mr. Tapan Mitra as Additional Independent Director for a 3-year term effective May 8, 2026Proposed Dr. Girdhar J. Gyani as Independent Director for a 3-year term starting August 1, 2026Extended the utilization period of unspent preferential issue funds by 18 months without changing objectsRe-appointed M/s. T R Chadha & Co LLP as Statutory Auditors for a second term of 5 years
👀 கவனிக்க வேண்டியவை
Investors should monitor the full financial results for revenue growth and margin trends, while the dividend and board strengthening reflect stable corporate governance.
Artemis Q4 FY26 Net Profit Surges 32.1% to ₹30.3 Cr; Revenue Up 16.4%
Artemis Medicare reported a strong Q4 FY26 with consolidated net profit growing 32.1% YoY to ₹3,028 Lacs. Revenue from operations increased by 16.4% to ₹27,923 Lacs, driven by higher ARPOB and international patient contributions. For the full year FY26, the company crossed the ₹1,000 crore revenue milestone, reaching ₹1,08,124 Lacs with a 26.2% growth in PAT. Operational efficiency at the flagship Gurgaon facility remains high, with ARPOB rising to ₹84,571 in Q4.
முக்கிய அம்சங்கள்
Consolidated Q4 FY26 Net Profit rose 32.1% YoY to ₹3,028 Lacs, while EBITDA grew 23.1% to ₹5,938 Lacs.Average Revenue Per Occupied Bed (ARPOB) increased to ₹84,571 in Q4 FY26 from ₹78,835 in the previous year.International patient revenue contributed 30.8% to the total net revenue in Q4, growing 13.5% YoY.Full-year FY26 consolidated revenue grew 15.4% to ₹1,08,124 Lacs with PAT reaching ₹10,372 Lacs.Bed capacity utilization stood at 64.6% for Q4, with the company progressing on its Raipur facility expansion.
👀 கவனிக்க வேண்டியவை
Investors should view the strong growth in ARPOB and international patient mix as positive indicators of margin expansion. The upcoming Raipur facility provides a clear growth catalyst for the next fiscal year.
Artemis Medicare Q4 FY26 PAT Jumps 32% YoY; Revenue Crosses INR 1,000 Cr in FY26
Artemis Medicare reported a strong financial performance for FY26, with consolidated revenue growing 15.4% to INR 1,081 crore and PAT increasing 26.2% to INR 104 crore. The company's core Gurgaon facility saw a 9.2% growth in inpatient volumes and a 7.3% rise in ARPOB to INR 84,571 in Q4. Management has outlined an aggressive expansion plan to reach approximately 2,000 beds by 2028, supported by a proposed INR 700 crore fundraise. Profitability margins showed healthy improvement, with Q4 EBITDA margins expanding to 21.3%.
முக்கிய அம்சங்கள்
Consolidated PAT for FY26 rose 26.2% YoY to INR 10,372 Lacs, with Q4 PAT growing 32.1% to INR 3,028 Lacs.Annual consolidated revenue from operations surpassed the INR 1,000 Cr milestone, reaching INR 1,08,124 Lacs.Operational efficiency improved as Q4 EBITDA margins expanded by 116 bps YoY to 21.3%.Aggressive expansion strategy targeting 2,000 beds by 2028, including a new 300+ bed hospital in Raipur expected by June 2026.Average Revenue Per Occupied Bed (ARPOB) for the Gurgaon facility grew 7.3% YoY to INR 84,571 in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should view the strong growth in ARPOB and inpatient volumes as a sign of robust demand and operational efficiency. Monitor the execution of the Raipur and South Delhi expansion projects and the terms of the proposed INR 700 crore fundraise as key growth drivers.
Artemis Medicare Recommends ₹0.45 Final Dividend and Extends Fund Utilization Period
Artemis Medicare Services has recommended a final dividend of ₹0.45 per share (45% of face value) for the financial year ended March 31, 2026. The board has also approved an 18-month extension for the utilization of unutilized funds from a previous preferential issue, maintaining the original objects. Key leadership updates include the appointment of Mr. Tapan Mitra and the proposed appointment of Dr. Girdhar J. Gyani as Independent Directors. Additionally, the company has proposed the re-appointment of its statutory auditors for a second five-year term until 2031.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.45 per equity share (45% of face value ₹1) for FY26.Approved an 18-month extension for the utilization of unutilized funds from the preferential issue.Appointed Mr. Tapan Mitra as an Independent Director for a 3-year term starting May 8, 2026.Proposed re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for a 5-year term until 2031.
👀 கவனிக்க வேண்டியவை
Investors should note the dividend payout and the extension of capital deployment timelines for preferential issue funds. Monitor the upcoming Annual General Meeting for final approvals on these resolutions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
